Recruiting
Acute lymphocytic leukaemia+1
RecruitingStudy of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Registered drugNo placebo
Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Registered drugNo placebo
- Disease:Acute lymphocytic leukaemiaPhiladelphia positive acute lymphocytic leukaemia
- Substances:Imatinib MesilateOlverembatinib+1
Countries:
Bulgaria
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Imatinib Mesilate
- Sponsor:Ascentage Pharma Group Inc.






